Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2016

Open Access 01-12-2016 | Research article

Ophiocordyceps formosana improves hyperglycemia and depression-like behavior in an STZ-induced diabetic mouse model

Authors: Chao-Wei Huang, Tzu-Wen Hong, Ying-Jing Wang, Ko-Chien Chen, Ju-Chun Pei, Tai-Yuan Chuang, Wen-Sung Lai, Sheng-Hong Tsai, Richard Chu, Wei-Cheng Chen, Lee-Yan Sheen, Satoru Takahashi, Shih-Torng Ding, Tang-Long Shen

Published in: BMC Complementary Medicine and Therapies | Issue 1/2016

Login to get access

Abstract

Background

A newly defined Cordyceps species, Ophiocordyceps formosana (O. formosana) has been implicated in multitudinous bioactivities, including lowering glucose and cholesterol levels and modulating the immune system. However, few literatures demonstrate sufficient evidence to support these proposed functions. Although the use of Cordyceps spp. has been previously addressed to improve insulin insensitivity and improve the detrimental symptoms of depression; its mechanistic nature remains unsettled. Herein, we reveal the effects of O. formosana in ameliorating hyperglycemia accompanied with depression.

Methods

Diabetes was induced in mice by employing streptozotocin(STZ), a chemical that is toxic to insulin-producing β cells of the pancreas. These streptozotocin (STZ)-induced diabetic mice showed combined symptoms of hyperglycemia and depressive behaviors. Twenty-four STZ-induced mice were randomly divided into 3 groups subjected to oral gavage with 100 μL solution of either PBS or 25 mg/mL Ophiocordyceps formosana extract (OFE) or 2 mg/mL rosiglitazone (Rosi, positive control group). Treatments were administered once per day for 28 days. An additional 6 mice without STZ induction were treated with PBS to serve as the control group. Insulin sensitivity was measured by a glucose tolerance test and levels of adiponectin in plasma and adipose tissue were also quantified. Behavioral tests were conducted and levels of monoamines in various brain regions relating to depression were evaluated.

Results

HPLC analysis uncovered three major constituents, adenosine, D-mannitol and cordycepin, within O. formosana similar to other prestigious medicinal Cordyceps spp.. STZ-induced diabetic mice demonstrated decreased body weight and subcutaneous adipose tissue, while these symptoms were recovered in mice receiving OFE treatment. Moreover, the OFE group displayed improved insulin sensitivity and elevated adiponectin within the plasma and adipose tissue. The anti-depressive effect of OFE was observed in various depression-related behavior tests. Concurrently, neurotransmitters, like 5-HT and dopamine in the frontal cortex, striatum and hippocampus were found to be up-regulated in OFE-treated mice.

Conclusions

Our findings illustrated, for the first time, the medicinal merits of O. formosana on Type I diabetes and hyperglycemia-induced depression. OFE were found to promote the expression of adiponectin, which is an adipokine involved in insulin sensitivity and hold anti-depressive effects. In addition, OFE administration also displayed altered levels of neurotransmitters in certain brain regions that may have contributed to its anti-depressive effect. Collectively, this current study provided insights to the potential therapeutic effects of O. formosana extracts in regards to hyperglycemia and its depressive complications.
Literature
1.
go back to reference Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001;358(9277):221–9.CrossRefPubMed Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001;358(9277):221–9.CrossRefPubMed
2.
go back to reference Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 diabetes through the life span: A position statement of the American Diabetes Association. Diabetes Care. 2014;37(7):2034–54.CrossRefPubMed Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 diabetes through the life span: A position statement of the American Diabetes Association. Diabetes Care. 2014;37(7):2034–54.CrossRefPubMed
4.
go back to reference Fukushima M, Hattori Y, Tsukada H, Koga K, Kajiwara E, Kawano K, Kobayashi T, Kamata K, Maitani Y. Adiponectin gene therapy of streptozotocin‐induced diabetic mice using hydrodynamic injection. J Gene Med. 2007;9(11):976–85.CrossRefPubMed Fukushima M, Hattori Y, Tsukada H, Koga K, Kajiwara E, Kawano K, Kobayashi T, Kamata K, Maitani Y. Adiponectin gene therapy of streptozotocin‐induced diabetic mice using hydrodynamic injection. J Gene Med. 2007;9(11):976–85.CrossRefPubMed
5.
go back to reference Fu Y, Luo N, Klein RL, Garvey WT. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res. 2005;46(7):1369–79.CrossRefPubMed Fu Y, Luo N, Klein RL, Garvey WT. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res. 2005;46(7):1369–79.CrossRefPubMed
6.
go back to reference Pereira RI, Snell-Bergeon JK, Erickson C, Schauer IE, Bergman BC, Rewers M, Maahs DM. Adiponectin dysregulation and insulin resistance in type 1 diabetes. J Clinical Endocrinol Metab. 2012;97(4):E642–7.CrossRef Pereira RI, Snell-Bergeon JK, Erickson C, Schauer IE, Bergman BC, Rewers M, Maahs DM. Adiponectin dysregulation and insulin resistance in type 1 diabetes. J Clinical Endocrinol Metab. 2012;97(4):E642–7.CrossRef
7.
go back to reference Blaslov K, Bulum T, Zibar K, Duvnjak L. Relationship between Adiponectin Level, Insulin Sensitivity, and Metabolic Syndrome in Type 1 Diabetic Patients, Int. J Endocrinol. 2013;535906. 6 pages. Blaslov K, Bulum T, Zibar K, Duvnjak L. Relationship between Adiponectin Level, Insulin Sensitivity, and Metabolic Syndrome in Type 1 Diabetic Patients, Int. J Endocrinol. 2013;535906. 6 pages.
8.
go back to reference Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes a meta-analysis. Diabetes Care. 2001;24(6):1069–78.CrossRefPubMed Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes a meta-analysis. Diabetes Care. 2001;24(6):1069–78.CrossRefPubMed
9.
go back to reference Goldney RD, Phillips PJ, Fisher LJ, Wilson DH. Diabetes, depression, and quality of life a population study. Diabetes Care. 2004;27(5):1066–70.CrossRefPubMed Goldney RD, Phillips PJ, Fisher LJ, Wilson DH. Diabetes, depression, and quality of life a population study. Diabetes Care. 2004;27(5):1066–70.CrossRefPubMed
10.
go back to reference Van Tilburg MA, McCaskill CC, Lane JD, Edwards CL, Bethel A, Feinglos MN, Surwit RS. Depressed mood is a factor in glycemic control in type 1 diabetes. Psychosom Med. 2001;63(4):551–5.CrossRefPubMed Van Tilburg MA, McCaskill CC, Lane JD, Edwards CL, Bethel A, Feinglos MN, Surwit RS. Depressed mood is a factor in glycemic control in type 1 diabetes. Psychosom Med. 2001;63(4):551–5.CrossRefPubMed
11.
go back to reference Gendelman N, Snell-Bergeon JK, McFann K, Kinney G, Wadwa RP, Bishop F, Rewers M, Maahs DM. Prevalence and correlates of depression in individuals with and without type 1 diabetes. Diabetes Care. 2009;32(4):575–9.CrossRefPubMedPubMedCentral Gendelman N, Snell-Bergeon JK, McFann K, Kinney G, Wadwa RP, Bishop F, Rewers M, Maahs DM. Prevalence and correlates of depression in individuals with and without type 1 diabetes. Diabetes Care. 2009;32(4):575–9.CrossRefPubMedPubMedCentral
12.
go back to reference Bijlsma EY, Chan JS, Olivier B, Veening JG, Millan MJ, Waldinger MD, Oosting RS. Sexual side effects of serotonergic antidepressants: Mediated by inhibition of serotonin on central dopamine release? Pharmacol Biochem Behav. 2014;121:88–101.CrossRefPubMed Bijlsma EY, Chan JS, Olivier B, Veening JG, Millan MJ, Waldinger MD, Oosting RS. Sexual side effects of serotonergic antidepressants: Mediated by inhibition of serotonin on central dopamine release? Pharmacol Biochem Behav. 2014;121:88–101.CrossRefPubMed
13.
go back to reference Hu XH, Bull SA, Hunkeler EM, Ming E, Lee JY, Fireman B, Markson LE. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004;65(7):959–65.CrossRefPubMed Hu XH, Bull SA, Hunkeler EM, Ming E, Lee JY, Fireman B, Markson LE. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004;65(7):959–65.CrossRefPubMed
14.
go back to reference Barnard K, Peveler RC, Holt RI. Antidepressant Medication as a Risk Factor for Type 2 Diabetes and Impaired Glucose Regulation Systematic review. Diabetes Care. 2013;36(10):3337–45.CrossRefPubMedPubMedCentral Barnard K, Peveler RC, Holt RI. Antidepressant Medication as a Risk Factor for Type 2 Diabetes and Impaired Glucose Regulation Systematic review. Diabetes Care. 2013;36(10):3337–45.CrossRefPubMedPubMedCentral
15.
go back to reference Rasgon NL, Kenna HA, Williams KE, Powers B, Wroolie T, Schatzberg AF. Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. Sci World J. 2010;10:321–8.CrossRef Rasgon NL, Kenna HA, Williams KE, Powers B, Wroolie T, Schatzberg AF. Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. Sci World J. 2010;10:321–8.CrossRef
16.
go back to reference Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–71.CrossRefPubMed Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–71.CrossRefPubMed
17.
go back to reference Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE, Rosenzweig-Lipson S. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx. 2005;2(4):590–611.CrossRefPubMedPubMedCentral Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE, Rosenzweig-Lipson S. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx. 2005;2(4):590–611.CrossRefPubMedPubMedCentral
18.
go back to reference Richelson E. The clinical relevance of antidepressant interaction with neurotransmitter transporters and receptors. Psychopharmacology Bull. 2011;36(4):133–50. Richelson E. The clinical relevance of antidepressant interaction with neurotransmitter transporters and receptors. Psychopharmacology Bull. 2011;36(4):133–50.
19.
go back to reference Bivens CH, Lebovitz HE, Feldman JM. Inhibition of hypoglycemia-induced growth hormone secretion by the serotonin antagonists cyproheptadine and methysergide. N Engl J Med. 1973;289:236–9.CrossRefPubMed Bivens CH, Lebovitz HE, Feldman JM. Inhibition of hypoglycemia-induced growth hormone secretion by the serotonin antagonists cyproheptadine and methysergide. N Engl J Med. 1973;289:236–9.CrossRefPubMed
20.
go back to reference Trujillo M, Scherer P. Adiponectin–journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257(2):167–75.CrossRefPubMed Trujillo M, Scherer P. Adiponectin–journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257(2):167–75.CrossRefPubMed
21.
go back to reference Liu J, Guo M, Zhang D, Cheng S-Y, Liu M, Ding J, Scherer PE, Liu F. Lu XY Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity. Proc Natl Acad Sci U S A. 2012;109(30):12248–53.CrossRefPubMedPubMedCentral Liu J, Guo M, Zhang D, Cheng S-Y, Liu M, Ding J, Scherer PE, Liu F. Lu XY Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity. Proc Natl Acad Sci U S A. 2012;109(30):12248–53.CrossRefPubMedPubMedCentral
22.
go back to reference Li CR, Fan MZ, Huang B, Wang SB, Li ZZ. The genus Cordyceps and its allies from Anhui I. Mycosystema. 2001;21(2):167–71. Li CR, Fan MZ, Huang B, Wang SB, Li ZZ. The genus Cordyceps and its allies from Anhui I. Mycosystema. 2001;21(2):167–71.
23.
go back to reference Zhou X, Gong Z, Su Y, Lin J, Tang K. Cordyceps fungi: natural products, pharmacological functions and developmental products. J Pharm Pharmacol. 2009;61(3):279–91.CrossRefPubMed Zhou X, Gong Z, Su Y, Lin J, Tang K. Cordyceps fungi: natural products, pharmacological functions and developmental products. J Pharm Pharmacol. 2009;61(3):279–91.CrossRefPubMed
24.
go back to reference Nishizawa K, Torii K, Kawasaki A, Katada M, Ito M, Terashita K, Aiso S, Matsuoka M. Antidepressant-like effect of Cordyceps sinensis in the mouse tail suspension test. Biol Pharm Bull. 2007;30(9):1758–62.CrossRefPubMed Nishizawa K, Torii K, Kawasaki A, Katada M, Ito M, Terashita K, Aiso S, Matsuoka M. Antidepressant-like effect of Cordyceps sinensis in the mouse tail suspension test. Biol Pharm Bull. 2007;30(9):1758–62.CrossRefPubMed
25.
go back to reference Guo J, Li C, Wang J, Liu Y, Zhang J. Vanadium-enriched Cordyceps sinensis, a contemporary treatment approach to both diabetes and depression in rats. Evid Based Complement Alternat Med. 2011;2011:450316. Guo J, Li C, Wang J, Liu Y, Zhang J. Vanadium-enriched Cordyceps sinensis, a contemporary treatment approach to both diabetes and depression in rats. Evid Based Complement Alternat Med. 2011;2011:450316.
26.
go back to reference Wang YW, Hong TW, Tai YL, Wang YJ, Tsai SH, Thi P: Evaluation of an epitypified Ophiocordyceps formosana (Cordyceps sl) for its pharmacological potential. Evid Based Complement Alternat Med. 2015. (In press). Wang YW, Hong TW, Tai YL, Wang YJ, Tsai SH, Thi P: Evaluation of an epitypified Ophiocordyceps formosana (Cordyceps sl) for its pharmacological potential. Evid Based Complement Alternat Med. 2015. (In press).
27.
go back to reference Chou SM, Lai WJ, Hong TW, Lai JY, Tsai SH, Chen YH, Yu SH, Kao CH, Chu R, Ding ST. Synergistic property of cordycepin in cultivated Cordyceps militaris-mediated apoptosis in human leukemia cells. Phytomedicine. 2014;21(12):1516–24.CrossRefPubMed Chou SM, Lai WJ, Hong TW, Lai JY, Tsai SH, Chen YH, Yu SH, Kao CH, Chu R, Ding ST. Synergistic property of cordycepin in cultivated Cordyceps militaris-mediated apoptosis in human leukemia cells. Phytomedicine. 2014;21(12):1516–24.CrossRefPubMed
28.
go back to reference Islam MS. Animal models of diabetic neuropathy: progress since 1960s. J Diabetes Res. 2013;149452:9. Islam MS. Animal models of diabetic neuropathy: progress since 1960s. J Diabetes Res. 2013;149452:9.
29.
go back to reference Soria B, Roche E, Berná G, León-Quinto T, Reig JA, Martín F. Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes. 2000;49(2):157–62.CrossRefPubMed Soria B, Roche E, Berná G, León-Quinto T, Reig JA, Martín F. Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes. 2000;49(2):157–62.CrossRefPubMed
30.
go back to reference Dorrell C, Grompe MT, Pan FC, Zhong Y, Canaday PS, Shultz LD, Greiner DL, Wright CV, Streeter PR, Grompe M. Isolation of mouse pancreatic alpha, beta, duct and acinar populations with cell surface markers. Mol Cell Endocrinol. 2011;339(1–2):144–50.CrossRefPubMedPubMedCentral Dorrell C, Grompe MT, Pan FC, Zhong Y, Canaday PS, Shultz LD, Greiner DL, Wright CV, Streeter PR, Grompe M. Isolation of mouse pancreatic alpha, beta, duct and acinar populations with cell surface markers. Mol Cell Endocrinol. 2011;339(1–2):144–50.CrossRefPubMedPubMedCentral
31.
go back to reference Andrikopoulos S, Blair AR, Deluca N, Fam BC, Proietto J. Evaluating the glucose tolerance test in mice. Am J Physiol Endocrinol Metab. 2008;295(6):1323–32.CrossRef Andrikopoulos S, Blair AR, Deluca N, Fam BC, Proietto J. Evaluating the glucose tolerance test in mice. Am J Physiol Endocrinol Metab. 2008;295(6):1323–32.CrossRef
32.
go back to reference Lai W-S, Xu B, Westphal KG, Paterlini M, Olivier B, Pavlidis P, Karayiorgou M, Gogos JA. Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc Natl Acad Sci U S A. 2006;103(45):16906–11.CrossRefPubMedPubMedCentral Lai W-S, Xu B, Westphal KG, Paterlini M, Olivier B, Pavlidis P, Karayiorgou M, Gogos JA. Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc Natl Acad Sci U S A. 2006;103(45):16906–11.CrossRefPubMedPubMedCentral
33.
go back to reference Huang CH, Kuo MT, Lai WS. Characterization of behavioural responses in different test contexts after a single social defeat in male golden hamsters (Mesocricetus auratus). Behav Process. 2011;86(1):94–101.CrossRef Huang CH, Kuo MT, Lai WS. Characterization of behavioural responses in different test contexts after a single social defeat in male golden hamsters (Mesocricetus auratus). Behav Process. 2011;86(1):94–101.CrossRef
34.
go back to reference Cryan JF, Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov. 2005;4(9):775–90.CrossRefPubMed Cryan JF, Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov. 2005;4(9):775–90.CrossRefPubMed
35.
go back to reference O’Leary OF. Cryan JF The tail-suspension test: a model for characterizing antidepressant activity in mice. Mood and Anxiety Related Phenotypes in Mice. 2009;42:119–37.CrossRef O’Leary OF. Cryan JF The tail-suspension test: a model for characterizing antidepressant activity in mice. Mood and Anxiety Related Phenotypes in Mice. 2009;42:119–37.CrossRef
36.
go back to reference Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl). 1985;85(3):367–70.CrossRef Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl). 1985;85(3):367–70.CrossRef
37.
go back to reference Can A, Dao DT, Terrillion CE, Piantadosi SC, Bhat S, Gould TD. The tail suspension test. J Vis Exp. 2012;59:3769.PubMed Can A, Dao DT, Terrillion CE, Piantadosi SC, Bhat S, Gould TD. The tail suspension test. J Vis Exp. 2012;59:3769.PubMed
38.
go back to reference Schindler M, Fischer S, Thieme R, Fischer B, Santos AN. cAMP-responsive element binding protein: a vital link in embryonic hormonal adaptation. Endocrinology. 2013;154(6):2208–21.CrossRefPubMed Schindler M, Fischer S, Thieme R, Fischer B, Santos AN. cAMP-responsive element binding protein: a vital link in embryonic hormonal adaptation. Endocrinology. 2013;154(6):2208–21.CrossRefPubMed
39.
go back to reference Abràmoff MD, Magalhães PJ, Ram SJ. Image processing with Image J. Biophoton Int. 2004;11:36–42. Abràmoff MD, Magalhães PJ, Ram SJ. Image processing with Image J. Biophoton Int. 2004;11:36–42.
40.
go back to reference Hao CW, Lai WS, Ho CT, Sheen LY. Antidepressant-like effect of lemon essential oil is through a modulation in the levels of norepinephrine, dopamine, and serotonin in mice: Use of the tail suspension test. J Funct Foods. 2013;5(1):370–9.CrossRef Hao CW, Lai WS, Ho CT, Sheen LY. Antidepressant-like effect of lemon essential oil is through a modulation in the levels of norepinephrine, dopamine, and serotonin in mice: Use of the tail suspension test. J Funct Foods. 2013;5(1):370–9.CrossRef
41.
go back to reference Hilakivi-Clarke L, Wozniak K, Durcan MJ, Linnoila M. Behavior of streptozotocin-diabetic mice in tests of exploration, locomotion, anxiety, depression and aggression. Physiol Behavior. 1990;48(3):429–33.CrossRef Hilakivi-Clarke L, Wozniak K, Durcan MJ, Linnoila M. Behavior of streptozotocin-diabetic mice in tests of exploration, locomotion, anxiety, depression and aggression. Physiol Behavior. 1990;48(3):429–33.CrossRef
42.
go back to reference Ohtani N, Ohta M, Sugano T. Microdialysis Study of Modification of Hypothalamic Neurotransmitters in Streptozotocin-Diabetic Rats. J Neurochem. 1997;69(4):1622–8.CrossRefPubMed Ohtani N, Ohta M, Sugano T. Microdialysis Study of Modification of Hypothalamic Neurotransmitters in Streptozotocin-Diabetic Rats. J Neurochem. 1997;69(4):1622–8.CrossRefPubMed
43.
go back to reference Kintscher U. Law RE PPARγ-mediated insulin sensitization: the importance of fat versus muscle. Am J Physiol Endocrinol Metab. 2005;288(2):E287–91.CrossRefPubMed Kintscher U. Law RE PPARγ-mediated insulin sensitization: the importance of fat versus muscle. Am J Physiol Endocrinol Metab. 2005;288(2):E287–91.CrossRefPubMed
44.
go back to reference Ahmed AAE, Al-Rasheed NM, Al-Rasheed NM. Antidepressant-like effects of rosiglitazone, a PPARγ agonist, in the rat forced swim and mouse tail suspension tests. Behav Pharmacol. 2009;20(7):635–42.CrossRef Ahmed AAE, Al-Rasheed NM, Al-Rasheed NM. Antidepressant-like effects of rosiglitazone, a PPARγ agonist, in the rat forced swim and mouse tail suspension tests. Behav Pharmacol. 2009;20(7):635–42.CrossRef
45.
go back to reference Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ. Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med. 2007;357(1):28–38.CrossRefPubMed Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ. Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med. 2007;357(1):28–38.CrossRefPubMed
46.
go back to reference Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S. Thiazolidinedione use, fluid retention, and congestive heart failure a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108(23):2941–8.CrossRefPubMed Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S. Thiazolidinedione use, fluid retention, and congestive heart failure a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108(23):2941–8.CrossRefPubMed
47.
go back to reference Plener PL, Molz E, Berger G, Schober E, Mönkemöller K, Denzer C, Goldbeck L, Holl RW. Depression, metabolic contorl, and antidepressant medication in young patients with type 1 diabetes. 2015;16(1):58-66. Plener PL, Molz E, Berger G, Schober E, Mönkemöller K, Denzer C, Goldbeck L, Holl RW. Depression, metabolic contorl, and antidepressant medication in young patients with type 1 diabetes. 2015;16(1):58-66.
48.
go back to reference Sawka AM, Burgart V, Zimmerman D. Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors. Diabetes Care. 2001;24(10):1845–6.CrossRefPubMed Sawka AM, Burgart V, Zimmerman D. Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors. Diabetes Care. 2001;24(10):1845–6.CrossRefPubMed
49.
go back to reference Balon TW, Jasman AP, Zhu J-S. A fermentation product of Cordyceps sinensis increases whole-body insulin sensitivity in rats. J Altern Complement Med. 2002;8(3):315–23.CrossRefPubMed Balon TW, Jasman AP, Zhu J-S. A fermentation product of Cordyceps sinensis increases whole-body insulin sensitivity in rats. J Altern Complement Med. 2002;8(3):315–23.CrossRefPubMed
50.
go back to reference Boden G, Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin Investing Drugs. 2006;15(3):243–50.CrossRef Boden G, Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin Investing Drugs. 2006;15(3):243–50.CrossRef
51.
go back to reference Whitehead J, Richards A, Hickman I, Macdonald G, Prins J. Adiponectin–a key adipokine in the metabolic syndrome. Diabetes Obes Metab. 2006;8(3):264–80.CrossRefPubMed Whitehead J, Richards A, Hickman I, Macdonald G, Prins J. Adiponectin–a key adipokine in the metabolic syndrome. Diabetes Obes Metab. 2006;8(3):264–80.CrossRefPubMed
52.
go back to reference Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol. 2004;219(1–2):9–15.CrossRefPubMed Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol. 2004;219(1–2):9–15.CrossRefPubMed
53.
go back to reference Narita K, Murata T, Takahashi T, Kosaka H, Omata N, Wada Y. Plasma levels of adiponectin and tumor necrosis factor-alpha in patients with remitted major depression receiving long-term maintenance antidepressant therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):1159–62.CrossRefPubMed Narita K, Murata T, Takahashi T, Kosaka H, Omata N, Wada Y. Plasma levels of adiponectin and tumor necrosis factor-alpha in patients with remitted major depression receiving long-term maintenance antidepressant therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):1159–62.CrossRefPubMed
54.
go back to reference Leo R, Di Lorenzo G, Tesauro M, Cola C, Fortuna E, Zanasi M, Troisi A, Siracusano A, Lauro R, Romeo F. Decreased plasma adiponectin concentration in major depression. Neurosci Lett. 2006;407(3):211–3.CrossRefPubMed Leo R, Di Lorenzo G, Tesauro M, Cola C, Fortuna E, Zanasi M, Troisi A, Siracusano A, Lauro R, Romeo F. Decreased plasma adiponectin concentration in major depression. Neurosci Lett. 2006;407(3):211–3.CrossRefPubMed
55.
go back to reference Yau SY, Li A, Hoo RL, Ching YP, Christie BR, Lee TM, Xu A, So KF. Physical exercise-induced hippocampal neurogenesis and antidepressant effects are mediated by the adipocyte hormone adiponectin. Proc Natl Acad Sci U S A. 2014;111(44):15810–5.CrossRefPubMedPubMedCentral Yau SY, Li A, Hoo RL, Ching YP, Christie BR, Lee TM, Xu A, So KF. Physical exercise-induced hippocampal neurogenesis and antidepressant effects are mediated by the adipocyte hormone adiponectin. Proc Natl Acad Sci U S A. 2014;111(44):15810–5.CrossRefPubMedPubMedCentral
57.
go back to reference Valente KD, Busatto FG. Depression and temporal lobe epilepsy represent an epiphenomenon sharing similar neural networks: clinical and brain structural evidences. Arq Neuropsiquiatr. 2013;71(3):183–90.CrossRefPubMed Valente KD, Busatto FG. Depression and temporal lobe epilepsy represent an epiphenomenon sharing similar neural networks: clinical and brain structural evidences. Arq Neuropsiquiatr. 2013;71(3):183–90.CrossRefPubMed
58.
go back to reference Lambert G, Johansson M, Ågren H, Friberg P. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiatry. 2000;57(8):787–93.CrossRefPubMed Lambert G, Johansson M, Ågren H, Friberg P. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiatry. 2000;57(8):787–93.CrossRefPubMed
59.
go back to reference Dalvi A, Lucki I. Murine models of depression. Psychopharmacology (Berl). 1999;147(1):14–6.CrossRef Dalvi A, Lucki I. Murine models of depression. Psychopharmacology (Berl). 1999;147(1):14–6.CrossRef
60.
go back to reference Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Reviews Neurosci. 2006;7:137–51.CrossRef Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Reviews Neurosci. 2006;7:137–51.CrossRef
61.
go back to reference Liu I, Niu C, Chi T, Kuo D, Cheng J. Investigations of the mechanism of the reduction of plasma glucose by cold-stress in streptozotocin-induced diabetic rats. Neuroscience. 1999;92(3):1137–42.CrossRefPubMed Liu I, Niu C, Chi T, Kuo D, Cheng J. Investigations of the mechanism of the reduction of plasma glucose by cold-stress in streptozotocin-induced diabetic rats. Neuroscience. 1999;92(3):1137–42.CrossRefPubMed
62.
go back to reference Trulson M, Himmel C. Effects of insulin and streptozotocin-induced diabetes on brain norepinephrine metabolism in Rats. J Neurochem. 1985;44(6):1873–6.CrossRefPubMed Trulson M, Himmel C. Effects of insulin and streptozotocin-induced diabetes on brain norepinephrine metabolism in Rats. J Neurochem. 1985;44(6):1873–6.CrossRefPubMed
63.
go back to reference Stone ML, Walker JL, Chisholm D, Craig ME, Donaghue KC, Crock P, Anderson D, Verge CF. The addition of rosiglitazone to insulin in adolescents with type 1 diabetes and poor glycaemic control: a randomized-controlled trial. Pediatr Diabetes. 2008;9(4 Pt 1):326–34.CrossRefPubMed Stone ML, Walker JL, Chisholm D, Craig ME, Donaghue KC, Crock P, Anderson D, Verge CF. The addition of rosiglitazone to insulin in adolescents with type 1 diabetes and poor glycaemic control: a randomized-controlled trial. Pediatr Diabetes. 2008;9(4 Pt 1):326–34.CrossRefPubMed
64.
go back to reference Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46–56.CrossRefPubMedPubMedCentral Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46–56.CrossRefPubMedPubMedCentral
65.
go back to reference Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732–41.CrossRefPubMedPubMedCentral Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732–41.CrossRefPubMedPubMedCentral
Metadata
Title
Ophiocordyceps formosana improves hyperglycemia and depression-like behavior in an STZ-induced diabetic mouse model
Authors
Chao-Wei Huang
Tzu-Wen Hong
Ying-Jing Wang
Ko-Chien Chen
Ju-Chun Pei
Tai-Yuan Chuang
Wen-Sung Lai
Sheng-Hong Tsai
Richard Chu
Wei-Cheng Chen
Lee-Yan Sheen
Satoru Takahashi
Shih-Torng Ding
Tang-Long Shen
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2016
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-016-1278-7

Other articles of this Issue 1/2016

BMC Complementary Medicine and Therapies 1/2016 Go to the issue